Stories

A recent qualitative risk assessment examining the carcinogenic potential of e-cigarettes has sparked strong reactions among public health experts and researchers. While the study suggests possible links between vaping and cancer-related mechanisms, several scientists have criticised its methodology and interpretation of evidence. Experts highlight that the review does not directly compare vaping with smoking, which they argue is essential for understanding relative risk. They also point out that detecting trace levels of potentially harmful substances does not necessarily translate into meaningful health risk, particularly without considering dosage and real-world exposure. Concerns have been raised about selective use of evidence and the absence of clear criteria for assessing causality, leading some to question the reliability of the conclusions. At the same time, researchers emphasise that while vaping is not risk-free, current evidence indicates significantly lower exposure to carcinogens compared to smoking. The debate reflects broader tensions in interpreting emerging evidence and communicating risk, particularly in areas where long-term epidemiological data are still limited.

Growing criticism is emerging over proposals to extend smoking-style bans to vaping in public places, with some commentators arguing that such measures lack a solid scientific basis. Critics point to existing evidence suggesting that second-hand exposure to vapour poses minimal risk to bystanders, questioning the justification for stricter restrictions. Concerns are also being raised that expanding bans could blur the distinction between smoking and vaping, potentially discouraging smokers from switching to lower-risk alternatives. The argument further suggests that implementing such policies may lead to unintended consequences, including reinforcing misconceptions about relative harm and misallocating public resources. At the centre of the debate is a broader question about whether public health policy should prioritise precautionary restrictions or remain closely aligned with existing scientific evidence on risk and exposure.

Growing debate is emerging around how nicotine is perceived in public health discussions, with some commentators arguing that it is often wrongly identified as the primary cause of smoking-related harm. The central claim is that it is the act of combustion—burning tobacco—that produces the vast majority of toxic chemicals responsible for disease, rather than nicotine itself. This perspective suggests that conflating nicotine with smoking risks misleading the public and obscuring the potential role of lower-risk alternatives in reducing harm. Proponents argue that clearer communication around relative risks could support more effective strategies to reduce smoking-related illness. At the same time, the issue remains contentious, particularly given nicotine’s addictive nature and concerns about uptake among non-smokers. The discussion reflects a broader divide in public health between precautionary approaches and harm reduction strategies.

France has introduced one of the strictest approaches in Europe to nicotine pouches, with new rules criminalising not only their sale but also personal possession and use. As of April 2026, these products are classified as a “toxic substance” under a health ministry decree, placing them under severe legal restrictions. Unlike in most other countries, individuals found in possession of nicotine pouches could face significant penalties, including large fines and even prison sentences under existing public health laws. The ban also extends beyond pouches to cover other non-medicinal oral nicotine products, while exempting approved nicotine replacement therapies. This move highlights an increasingly strict regulatory stance in France, and has sparked wider debate about proportionality, enforcement, and the role of alternative nicotine products within public health policy.

Growing concern is emerging in Bangladesh as anti-tobacco organisations warn against proposed changes to national legislation that would remove key restrictions on e-cigarettes. The planned amendments include lifting the ban on these products and allowing the display of tobacco at points of sale, raising fears about increased visibility and access. Health advocates argue that such measures could weaken existing tobacco control efforts and contribute to higher rates of nicotine use, particularly among young people. Critics also stress that emerging nicotine products may act as a gateway to addiction, warning that loosening regulations could open the door to stronger industry influence. The debate highlights broader tensions between regulatory changes and public health priorities in a country already facing a significant burden from tobacco-related harm.

Brazil’s tobacco exports saw a decline in the first two months of 2026, reflecting shifting demand and market conditions in key international destinations. Despite this drop in volume, overall export levels remain above the long-term average, indicating continued resilience in the sector. The country remains one of the world’s leading tobacco exporters, with the majority of production destined for foreign markets. Recent fluctuations are linked in part to changes in demand from major buyers, as well as broader trade dynamics affecting agricultural commodities. While short-term performance has softened, the data suggests that Brazil’s tobacco industry continues to maintain a strong position globally. The trend highlights how export performance can vary in the short term while still remaining stable over a longer horizon.

The GFN26 team has announced that the Global Forum on Nicotine’s online conference programme is now live. A keynote session will take place on Thursday, 4 June 2026 at 09:30 in the main auditorium, where Dr Garrett McGovern, Professor Jean-François Etter and Dr Arielle Selya will discuss the impact of prohibition on health and ethics. Registration is now open, with further details available on the official website.

Sweden has reached a significant public health milestone, with daily smoking rates falling to just 3.7 percent—well below the threshold commonly used to define a “smoke-free” society. This places the country at the forefront of global efforts to reduce smoking prevalence, far ahead of most EU member states. The achievement is often linked to long-term trends showing a steady decline in cigarette use alongside the availability of alternative nicotine products. Sweden has consistently recorded some of the lowest smoking rates in Europe, reinforcing its position as a leading case study in tobacco control. The milestone is now fuelling wider debate about which policies and behavioural shifts have driven this progress, and whether similar approaches could be replicated in other countries.

Growing concern is being raised about a new generation of young people developing nicotine dependence through emerging products such as e-cigarettes and nicotine pouches. Critics argue that these products, often marketed as safer alternatives, may still contribute to addiction among adolescents and young adults. The discussion highlights how early exposure to nicotine increases the risk of long-term dependence, particularly given the vulnerability of the developing brain. At the same time, rising use of newer nicotine formats among youth is fuelling debate over whether current public health strategies are adequately addressing changing patterns of consumption. The issue reflects broader concerns that progress in reducing smoking rates could be offset by the growth of alternative nicotine products.

Growing criticism is emerging around the UK’s Tobacco and Vapes Bill, with some commentators arguing that the legislation could undermine its own public health objectives. Critics claim that measures such as the generational smoking ban and tighter restrictions on alternative nicotine products risk driving consumers towards illicit markets rather than reducing overall harm. Concerns are also being raised about the potential unintended consequences for small retailers and the wider high street, as stricter rules may disproportionately impact legal businesses while leaving illegal trade less affected. The argument centres on whether innovation—particularly the rise of vaping and other alternatives—has already played a significant role in reducing smoking rates without the need for heavy-handed regulation. At the heart of the debate is a broader question about the effectiveness of prohibition-style policies versus harm reduction approaches in achieving long-term public health goals.